Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye
Medical Science Monitor · 2025
DOI: 10.12659/msm.947817 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Medical Science Monitor, 2025. Verfasst von Melike Yüksel Yavuz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, İzmir Katip Çelebi University, Faculty of Medicine, İzmir, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege, Patientensicherheit
Abstract (Originalsprache)
BACKGROUND In this study conducted in a single center in Türkiye, we aimed to investigate the effect of sex differences on survival and treatment adverse effects in 100 patients with advanced non-small cell lung carcinoma (NSCLC) treated with immune checkpoint inhibitors. MATERIAL AND METHODS This was a single-center, retrospective, observational study. All 100 patients with non-small cell lung carcinoma admitted to the Pulmonary and Medical Oncology Department of a Training and Research Hospital between January 2018 and March 2024 were evaluated. Demographic data, cancer characteristics, overall survival, and adverse effects of immune checkpoint inhibitors were investigated in the male and female patient groups. Patients were treated with nivolumab and atezolizumab as immune checkpoint inhibitors (ICI). RESULTS This study included 100 patients, with 88 (88%) men and 12 (12%) women. The average age of the patients was 64.3±8.5 years, 63% had adenocarcinoma, and 80.6% of all patients were stage 4. Although overall survival was significantly lower in women compared to men in univariate analysis (P=0.047), this difference disappeared in multivariate analysis (P=0.168). Adverse effects were observed in 91% of the patients. Pleural effusion (P=0.040), hypothyroidism (P=0.003), and rash (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonology, İzmir Katip Çelebi University, Faculty of Medicine, İzmir, Turkey.
- Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey.
- Department of Pulmonology, İzmir Katip Çelebi University, Faculty of Medicine,, İzmir, Turkey.
- Department of Medical Oncology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey.
ORCID-Profile: Melike Yüksel Yavuz, Filiz Karapinar, Ceyda Anar, Mehdi Ok, Sema Ertürk, Mine Gayaf, Fatma Demirci Üçsular, Gülru Polat
Zitieren
APA
Yüksel Yavuz, M., Karapinar, F., Anar, C., Ok, M., Ertürk, S., Gayaf, M., Demirci Üçsular, F., & Polat, G. (2025). Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye. Medical Science Monitor. https://doi.org/10.12659/msm.947817
Vancouver
Yüksel Yavuz M, Karapinar F, Anar C, Ok M, Ertürk S, Gayaf M, et al. Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye. Medical Science Monitor. 2025. doi:10.12659/msm.947817
BibTeX
@article{YkselYavuz2025,
author = {Yüksel Yavuz, Melike and Karapinar, Filiz and Anar, Ceyda and Ok, Mehdi and Ertürk, Sema and Gayaf, Mine and Demirci Üçsular, Fatma and Polat, Gülru},
title = {Association of Sex with Survival and Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Experience in Türkiye},
journal = {Medical Science Monitor},
year = {2025},
doi = {10.12659/msm.947817}
}
EUVIMED